On November 8, 2021 Ascendis Pharma A/S (Nasdaq: ASND) reported that provided an update on the Company’s previously announced $25 million American Depositary Shares (ADS) Share Repurchase Program (Press release, Ascendis Pharma, NOV 8, 2021, View Source [SID1234594703]). Each ADS represents one ordinary share of Ascendis Pharma A/S. The program is executed under Rules 10b-18 and 10b5-1 of the U.S. securities regulations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In accordance with the program initiated on November 1, 2021, Ascendis Pharma A/S is authorized to repurchase up to $25 million of ADSs in the period starting November 1, 2021 and expected to end no later than December 31, 2021. A maximum of 300,000 ADS in total can be repurchased during the trading period. The maximum number of ADS that can be repurchased on a single trading day may not exceed 10% of the average daily trading volume of Ascendis Pharma A/S ADS, in the prior full four weeks of trading.

Since the initiation of the program, the following transactions have been executed.

Trade Date
Number of ADS Weighted Average
Purchase Price

Total Value*
November 1, 2021 24,540 $159.15 $3,906,181
November 2, 2021 24,631 $162.99 $4,015,444
November 3, 2021 24,631 $163.09 $4,017,730
November 4, 2021 24,631 $161.09 $3,968,488
November 5, 2021 23,989 $160.69 $3,855,409
Purchased under the program 122,422 $161.41 $19,763,252
*Total value includes fees and costs associated with the repurchase program.

Following these transactions, Ascendis Pharma A/S has repurchased a total of 122,422 ADSs under the Share Repurchase Program.